Skip to main content

Table 1 Basic clinical conditions and biochemical parameters of the T2DM patients after intensive insulin therapy

From: Effect of rosiglitazone on inflammatory cytokines and oxidative stress after intensive insulin therapy in patients with newly diagnosed type 2 diabetes

  Rosiglitazone Metformin Rosiglitazone plus metformin Insulin aspart 30
Baseline 48 weeks Baseline 48 weeks Baseline 48 weeks Baseline 48 weeks
n 40 40 39 39 36 36 41 41
Age (years) 40.36 ± 10.02 40.36 ± 10.02 42.13 ± 9.54 42.13 ± 9.54 42.36 ± 9.52 42.36 ± 9.52 41.62 ± 9.87 41.62 ± 9.87
Sex (male/female) 21/19 21/19 23/16 23/16 20/16 20/16 24/17 24/17
Weight (kg) 69.57 ± 5.37 73.23 ± 9.55* 70.08 ± 11.15 66.34 ± 11.76* 72.69 ± 10.61 73.08 ± 9.38 69.22 ± 12.21 74.52 ± 11.63b
BMI (kg/m2) 27.17 ± 2.74 29.55 ± 7.29* 28,32. ± 3.63 26.01 ± 6.71* 28.11 ± 6.85 28.28 ± 8.52 27.75 ± 7.62 30.63 ± 8.92*b
BP (mmHg) 132/76 134/80 136/80 138/76 132/78 130/76 134/78 138/80
HbA1c (%) 13.41 ± 4.22 8.85 ± 2.66 12.72 ± 5.85 7.97 ± 3.89 15.82 ± 5.53 7.56 ± 3.95a 13.58 ± 4.64 6.35 ± 3.06ab
GAD Negative Negative Negative Negative Negative Negative Negative Negative
ICA Negative Negative Negative Negative Negative Negative Negative Negative
RSG (mg) 4 4 NA NA 4 4 NA NA
Metformin (g) NA NA 1.81 ± 0.89 1.89 ± 0.93 1.98 ± 0.56 2.05 ± 0.83 NA NA
GlucoseFasting (mmol/L) 6.72 ± 2.39 8.48 ± 2.42* 6.44 ± 3.16 7.39 ± 3.54 * 6.63 ± 3.84 7.54 ± 2.13*a 6.68 ± 2.58 6.85 ± 3.66ab
Glucose2-hour postprandial (mmol/L) 8.58 ± 4.46 13.50 ± 3.76 8.05 ± 4.17 13.72 ± 4.48 8.96 ± 2.63 10.03 ± 3.89ab 8.93 ± 3.74 9.48 ± 3.73ab
C-peptideFasting (ng/mL) 3.73 ± 1.01 4.66 ± 2.63 4.03 ± 2.22 3.96 ± 1.57 3.88 ± 1.95 3.99 ± 1.05 4.14 ± 1.36 4.01 ± 1.74
InsulinFasting (mIU/L) 18.62 ± 10.52 16.76 ± 8.59 19.70 ± 11.15 17.34 ± 9.56 17.25 ± 7.23 16.64 ± 6.53   
HOMA-IR 6.92 ± 2.14 5.89 ± 3.25* 7.11 ± 3.35 5.04 ± 2.31* 6.59 ± 3.28 4.72 ± 3.68a 7.56 ± 3.45 6.93 ± 3.72ab
HOMA-β 48.26 ± 20.15 47.27 ± 15.13 49.37 ± 18.81 48.48 ± 19.64 50.38 ± 30.58 49.49 ± 26.10 48.64 ± 18.63 49.53 ± 16.68
TG (mmol/L) 1.53 ± 0.96 1.56 ± 0.87 1.67 ± 0.78 1.36 ± 0.99* 1.92 ± 1.08 1.24 ± 0.85* 1.89 ± 0.75 1.68 ± 0.84
CH (mmol/L 5.63 ± 2.63 5.08 ± 3.95 5.92 ± 3.33 5.35 ± 3.45 5.41 ± 2.52 5.20 ± 2.47 5.57 ± 3.84 5.67 ± 2.68
LDL (mmol/L) 2.48 ± 1.58 2.17 ± 2.56 2.96 ± 1.99 2.63 ± 2.02 2.78 ± 2.22 2.05 ± 2.65 2.53 ± 1.56 3.32 ± 1.46
HDL (mmol/L) 0.85 ± 0.37 0.88 ± 0.62 0.95 ± 0.64 0.98 ± 0.35 0.97 ± 0.84 0.90 ± 0.76 0.87 ± 0.45 0.98 ± 0.56
ALT (U/L 48.20 ± 9.35 46.09 ± 7.64 46.64 ± 10.24 48.67 ± 8.28 47.11 ± 5.69 45.87 ± 8.47 47.65 ± 10.75 46.56 ± 8.47
AST (U/L) 42.07 ± 10.84 39.53 ± 8.78 44.33 ± 11.58 42.16 ± 10.93 41.33 ± 8.55 39.52 ± 9.19 43.64 ± 7.76 42.58 ± 10.76
AKP (U/L) 98.66 ± 6.87 97.23 ± 8.30 96.47 ± 7.77 98.54 ± 9.39 97.77 ± 7.22 95.65 ± 7.46 97.64 ± 8.74 98.75 ± 10.75
γ-GT (U/L) 58.65 ± 5.11 42.94 ± 8.28 * 59.26 ± 7.87 49.51 ± 9.67 * 57.09 ± 6.43 40.10 ± 9.33* 59.46 ± 6.59 58.45 ± 7.55
  1. P < 0.05, compared with the baseline level
  2. P < 0.01, compared with the baseline level
  3. aP < 0.05, compared with the rosiglitazone group after treatment
  4. bP < 0.05 compared with the metformin group after treatment